G1 Therapeutics Receives $33,000,000 Series B Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b85b0b86-ca85-462d-998f-22b61024aa30
Date
2/5/2015
Company Name
G1 Therapeutics
Mailing Address
79 T.W. Alexander Drive Research Triangle Park, NC 27709 USA
Company Description
G1 Therapeutics is working to commercialize a proprietary small molecule-based approach to protect the bone marrow from damage due to chemotherapy or radiation.
Website
http://www.g1therapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$33,000,000
Transaction Round
Series B
Proceeds Purposes
G1 plans to use the proceeds to advance its lead program G1T28, a highly potent and selective CDK4/6 inhibitor, through proof of concept as an antineoplastic agent and as a bone marrow chemoprotectant. G1T28 is currently being evaluated in Phase 1a clinical trials to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers. Data collected from this study will inform the dose and schedule for multiple Phase 1b / 2a clinical trials in cancer patients, which are expected to begin in 2015.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor